Search
Vaccines Treatment Options
A collection of 948 research studies where Vaccines is the interventional treatment. These studies are located in the United States. Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
349 - 360 of 948
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Self-Administered Nasal Influenza Feasibility Study
Completed
The purpose of this prospective, open-label clinical trial is to evaluate the immunogenicity of self-administered (SA) live, attenuated influenza vaccine (LAIV) in comparison with healthcare worker administered (HCWA) LAIV and to evaluate the feasibility of group self-administration of LAIV.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
02/13/2023
Locations: Naval Medical Center San Diego, San Diego, California +1 locations
Conditions: Influenza
The BOOSTED (Booster Options Or Switching Tested for Effectiveness and Downsides Study) Trial (COVID-19)
Completed
While both heterologous (mixing) and homologous (matching) vaccine regimens are now considered standard of care, post-vaccination complications and long-term effects of the different vaccination regimens have not been thoroughly studied. There is a pressing need to investigate the longitudinal effects of the mixing and matching vaccine-booster approaches. This study proposes to utilize the existing digital infrastructure of the COVID-19 Citizen Science (CCS) study on the Eureka Research Platform... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: UCSF Parnassus, San Francisco, California
Conditions: COVID-19, Vaccine Reaction, COVID-19 Pandemic
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
Completed
This is a pilot phase 1, open-label, single center, multi-dose, dose-escalation study of BMS-936558 in combination with or without a peptide vaccine.
The purpose of this study is to test the side effects of an investigational vaccine with an immune booster. Investigators also wish to find out its effects on the patient's immune system and whether it will shrink their melanoma.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
01/17/2023
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Melanoma (Skin)
A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)
Completed
The goal of this study is to evaluate the safety, tolerability, and immunogenicity of the Pneumococcal Conjugate Vaccines (PCVs) V114 and Prevnar 13™ in healthy infants switched from Prevnar 13™ to V114 during the four-dose PCV immunization schedule.
Gender:
ALL
Ages:
Between 42 days and 90 days
Trial Updated:
01/12/2023
Locations: Alabama Clinical Therapeutics ( Site 0015), Birmingham, Alabama +33 locations
Conditions: Pneumococcal Infections
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
Active Not Recruiting
This randomized phase II trial studies how well multi-epitope folate receptor alpha peptide vaccine, sargramostim (GM-CSF), and cyclophosphamide work to prevent the recurrence of stage 1-3 triple negative breast cancer. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing th... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/12/2023
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +11 locations
Conditions: Bilateral Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma, Unilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage II Breast Cancer AJCC v6 and v7
Safety of RIV4 Versus IIV4 in Pregnant Women
Completed
This is a prospective, randomized clinical trial. During the study, pregnant women will be randomized (1:1) to receive RIV4 or IIV4. Vaccines will be administered by licensed providers.
Prior influenza vaccine history will be verified by medical record review when possible.
Injection-site (local) and systemic reaction data will be assessed on vaccination day and during the 8 days following vaccination using either identical web-based or paper diaries, depending on study participant preference.... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/09/2023
Locations: Boston Medical Center, Boston, Massachusetts +2 locations
Conditions: Safety, Adverse Event Following Immunisation, Birth Outcomes
Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients
Completed
This pilot clinical trial studies the safety of a dendritic cell vaccine when given with gemcitabine hydrochloride in treating patients with breast cancer that has spread beyond the breast and local lymph nodes to other organs in the body. The vaccine is made up of natural cells found in the blood, called dendritic cells, and peptides, or small fragments of protein which are loaded onto the dendritic cells. This combination may help activate the immune system against stromal cells, which are cel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2022
Locations: University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio +1 locations
Conditions: Breast Cancer, Metastatic Breast Cancer
Safety and Immunogenicity of a Nipah Virus Vaccine
Completed
A first-in-human, phase 1 trial is to be conducted in a healthy adult population in the US to assess the safety and immunogenicity of three ascending Nipah vaccine (HeV-sG-V; Hendra virus soluble glycoprotein vaccine) dosages. Different dosing regimens and number of doses will also be explored.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
11/16/2022
Locations: Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, Ohio
Conditions: Nipah Virus Infection
Tdap Vaccine Safety for Plasma Donors
Completed
This is a prospective, open label, single-arm, multi-center, Phase 1 study measuring the safety and tetanus antibody responses to Tdap vaccine administered to plasma donors every 3 months ±1 week for 12 months (5 vaccinations) with a 6 month follow-up after the last vaccination. After obtaining informed consent and screening for eligibility including plasmapheresis donor eligibility, subjects will have other baseline assessments performed and if eligible, will receive the scheduled vaccinations,... Read More
Gender:
ALL
Ages:
Between 18 years and 63 years
Trial Updated:
11/14/2022
Locations: GCAM Eagle Pass Center, Eagle Pass, Texas +1 locations
Conditions: Tetanus
Flucelvax (TIVc or QIVc) Pregnancy Registry
Completed
The study is a population based prospective cohort study designed to collect data on pregnancy outcomes and events of interest among women immunized with the TIVc or QIVc vaccine during pregnancy.
Gender:
FEMALE
Ages:
All
Trial Updated:
11/03/2022
Locations: Syneos Health, Wilmington, North Carolina
Conditions: Influenza, Human, Pregnancy, Birth Defect
COVID Vaccine Immunity in Kidney Transplant Recipients
Withdrawn
50 end-stage renal disease (ESRD) patients whom have had at least 2 doses of messenger ribonucleic acid (mRNA) vaccine, and undergoing transplantation at the University of Alabama at Birmingham (UAB) will be enrolled. The third mRNA vaccine will be given 3 months post transplant, and the 4th mRNA vaccine will be given 3 months following this. Blood samples will be collected and shipped to Viracor on day of transplant, and at months 1, 3, 4, 6, and 12 for spike protein and t cell assay.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/25/2022
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: End Stage Renal Disease, Kidney Transplant; Complications
Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine
Unknown
This is a multicenter, international, randomized, active-controlled platform study with each sub-study designed to randomize subjects to receive a single injection with UB-612 or a comparator COVID-19 vaccine in 1:1 ratio.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
10/11/2022
Locations: PanAmerican Clinical Research, Brownsville, Texas +6 locations
Conditions: COVID-19 Vaccines
349 - 360 of 948